These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7071808)

  • 1. Kinetic study of factor X during oral anticoagulation with acenocoumarol: potential value for the initiation of treatment.
    Aiach M; Fiessinger JN; Capron L; Nussas C; Housset E; Leclerc M
    Thromb Haemost; 1982 Feb; 47(1):69-71. PubMed ID: 7071808
    [No Abstract]   [Full Text] [Related]  

  • 2. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?
    Barcellona D; Vannini ML; Fenu L; Balestrieri C; Marongiu F
    Thromb Haemost; 1998 Dec; 80(6):899-902. PubMed ID: 9869157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of action of oral anticoagulants].
    Uszyński L
    Acta Haematol Pol; 1972; 3(2):133-9. PubMed ID: 4655612
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of factor VII -323 Del/Ins polymorphism on the daily variability of factor VIIc and INR in steady anticoagulated patients with acenocoumarol.
    Roldán V; Corral J; Marín F; Vicente V; González-Conejero R
    J Thromb Haemost; 2004 Dec; 2(12):2264-5. PubMed ID: 15613046
    [No Abstract]   [Full Text] [Related]  

  • 6. Abrupt versus gradual withdrawal of vitamin K antagonist treatment in patients with venous thromboembolic disease: assessment of hypercoagulability and clinical outcome.
    de Groot MR; Njo TL; van Marwijk Kooy M; Büller HR
    Clin Lab; 2000; 46(11-12):575-81. PubMed ID: 11109505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).
    Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S
    Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
    van Leeuwen Y; Rosendaal FR; van der Meer FJ
    Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A retrospective survey on practice of oral anticoagulant therapy in patients with cardiovascular diseases].
    Katona A; Márk L
    Orv Hetil; 2004 Aug; 145(32):1643-7. PubMed ID: 15384862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anticoagulant treatment of Eales' disease.
    Casanovas J; Castillo R
    Bibl Ophthalmol; 1968; 76():166-71. PubMed ID: 5674839
    [No Abstract]   [Full Text] [Related]  

  • 11. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation.
    Bruhn HD; Zurborn KH
    J Heart Valve Dis; 1995 Mar; 4(2):138-40. PubMed ID: 8556173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of Quick/INR values of whole capillary blood (CoaguChek Plus) and venous citrate plasma in patients with and without oral anticoagulation].
    Burri S; Demarmels Biasiutti F; Lämmle B; Wuillemin WA
    Schweiz Med Wochenschr; 1998 Oct; 128(44):1723-9. PubMed ID: 9846345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experiences with anticoagulant long term treatment of predominantly cardiologic patients].
    Kubicek F; Praschl E
    Wien Klin Wochenschr; 1968 Nov; 80(44):813-9. PubMed ID: 4974107
    [No Abstract]   [Full Text] [Related]  

  • 15. Ticlopidine antagonizes acenocoumarol treatment.
    Salar A; Domenech P; Martínez F
    Thromb Haemost; 1997 Jan; 77(1):223-4. PubMed ID: 9031484
    [No Abstract]   [Full Text] [Related]  

  • 16. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence.
    Palareti G; Legnani C; Cosmi B; Guazzaloca G; Cini M; Mattarozzi S
    J Thromb Haemost; 2005 May; 3(5):955-61. PubMed ID: 15869591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment.
    Bertina RM; Westhoek-Kuipers ME; Alderkamp GH
    Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant therapy during pregnancy. A new approach.
    Olwin JH; Koppel JL
    Obstet Gynecol; 1969 Dec; 34(6):847-52. PubMed ID: 5366028
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosuvastatin-acenocoumarol interaction.
    Mondillo S; Ballo P; Galderisi M
    Clin Ther; 2005 Jun; 27(6):782-4. PubMed ID: 16117985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial.
    Aramendi JI; Mestres CA; Martinez-León J; Campos V; Muñoz G; Navas C
    Eur J Cardiothorac Surg; 2005 May; 27(5):854-60. PubMed ID: 15848326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.